Risk Management and Pharmacovigilance Presentation from 2010 Conference
1. Presented at Pharmacovigilance 2010, January 21-22, 2010
Dr. Bhaswat S. Chakraborty
Senior VP, R&D, Cadila Pharmaceuticals
Jnauary 22, 2009
2. Risk Management and
Pharmacovigilance
Increased focus on safety and risk management is a global issue
with diminishing boundaries
Knowledge and experience of the drug and its life-cycle further
develops as we understand its use and hazards
Development of global risk management plan rather than
individual region or country Risk
Management plans would be an important step forward to more
effectively and accurately assess the safety of pharmaceutical drug
products
An early risk management planning between company, regulator
and healthcare professionals is key for successful product life cycle
management
Risk Communication Plan between Company, Regulator,
Healthcare Professionals and Patients is getting more transparent
3. And Yet…
Despite this increased importance, stakeholders still
use traditional methods for PV
Conservative methods do not capture many SAEs and
USAEs that are possible to capture from huge
databases without further experimentation
Data mining is one such approach
Data mining can help find unrecognized toxic signals
4. Two categories of approved drug
Category 1
Those who are unequivocally superior to existing drugs
of that class in efficacy
May or may not be superior in safety
Category 2
Those who are not superior to existing drugs of that
class in efficacy
Non-inferior
Superior to placebo but inferior to existing standard
care
May or may not be superior in safety
5. Premature Approval?
Many Category 2 drugs whose complete safety profile is
still unknown were approved
In some cases, drugs are approved despite identification of
SAEs in premarketing trials
Alosetron hydrochloride – ischemic colitis
Grepafloxacin hydrochloride – QT prolongation and deaths
Rofecoxib – heart attack and stroke (long-term, high-dosage use)
They were all subsequently withdrawn from the market
because of these SAEs
6. Market Uptake and Sales Volume
Many drugs whose complete safety profile is still unknown
actually have/had a rapid market and very high sales volume
through increased Rx.
Promotion of early use of new drugs by sponsors
Physicians' adoption of such drugs
Direct-to-consumer drug advertising
Pharma companies concern for patent life, a desire to mold
prescribing habits prior to the market entry of competitors
“Ramp-up" in sales encourages investors and increase stock
prices.
New drug safety may be further compromised by the failure to
conduct postmarketing studies
7.
8.
9. J. Herson. In Data and Safety Monitoring Committees in Clinical Trials
10. Having an Adverse Events
Database
Is not a bad idea
All good pharma companies have AE database
Almost all developed country regulatory agencies
have AE database
The WHO Uppsala Monitoring Centre (UMC) now
receive >1,000,000 reports per year
Such databses can really help in bringing down drug
induced morbidity
11. Desirable Attributes of AE Database
Software
Should be well integrated with Clinical data
management software
User friendly
Individual reports management features
Easy for query
Line listing of the entire database or part is possible
and easy
Data extraction is easy, with desirable filters
May also keep track of postmarketing Rx utility and
complaints data
12. Collection of ICSRs from CADRMP
or any comprehensive database
Conversion of free text to structured information
Data cleaning and duplicate detection
Applying quantitative or statistical methods
Computing an accurate measure for SD
Gavali, Kulkarni, Kumar and Chakraborty (2009), Ind J Pharmacol, 41, 162-166
13. Targeted Event Y All other events Total
Targeted
A B A+B
Drug X
All other
C D C+D
drugs
Total A+C B+D A+B+C+D
14. Criteria for a Toxic Disproportional ADR
A ( A +B )
PRR =
C (C +D )
AB Significant disproportional
ROR = Signal is detected when χ2
C D is ≥ 4.0 and the rest ≥ 2.0
χ =
2 (Observed − Expected ) 2
Expected
15. Casestudy Example: Propranolol-Bradycardia
Not
PRR = 2.51 Bradycardia
Bradycardia
ROR = 2.58 Propranolol
4 82
HCL
χ2 = 3.26
Not Propranolol
52 2749
HCL
Therefore, bradycardia is not a significant
disproportional signal (Serious Adverse Event)
associated with Propranolol
Gavali, Kulkarni, Kumar and Chakraborty (2009), Ind J Pharmacol, 41, 162-166
Alosetron is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS). Grepafloxacin hydrochloride (trade name Raxar, Glaxo Wellcome) is an oral broad-spectrum quinoline antibiotic agent used to treat bacterial infection. Rofecoxib is a nonsteroidal anti-inflammatory drug (NSAId) that has now been withdrawn over safety concerns.
Alosetron is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS). Grepafloxacin hydrochloride (trade name Raxar, Glaxo Wellcome) is an oral broad-spectrum quinoline antibiotic agent used to treat bacterial infection. Rofecoxib is a nonsteroidal anti-inflammatory drug (NSAId) that has now been withdrawn over safety concerns.
In the USA, a black box warning (also sometimes called a black label warning or boxed warning ) is a type of warning that appears on the package insert for prescription drugs that may cause serious adverse effects. It is so named for the black border that usually surrounds the text of the warning.
Proportional Reporting Ratio (PRR); Reporting Odds Ratio (ROR);